Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. 
The ARCUS technology platform allows for delivery of medication through inhalation. It has been used in clinical trials across a broad spectrum of applications: local and systemic disease targets, large and small molecules, and a wide range of doses. The Company has two clinical-stage programs that use the ARCUS technology: CVT-301 (symptoms of OFF periods in Parkinson’s disease) and CVT-427 (acute treatment of migraine).

Type
Public
HQ
Ardsley, US
Founded
1995
Size (employees)
597 (est)+12%
Website
acorda.com
Acorda Therapeutics was founded in 1995 and is headquartered in Ardsley, US

Acorda Therapeutics Office Locations

Acorda Therapeutics has offices in Ardsley, Chelsea, South San Francisco and Waltham
Ardsley, US (HQ)
420 Saw Mill River Rd
Waltham, US
283 Bear Hill Rd
South San Francisco, US
701 Gateway Blvd
Chelsea, US
190 Everett Ave

Acorda Therapeutics Data and Metrics

Acorda Therapeutics Financial Metrics

Acorda Therapeutics's revenue was reported to be $519.6 m in FY, 2016 which is a 5% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

519.6 m

Revenue growth (FY, 2015 - FY, 2016), %

5%

Gross profit (FY, 2016)

412.1 m

Gross profit margin (FY, 2016), %

79%

Net income (FY, 2016)

(35.6 m)

EBIT (FY, 2016)

(36 m)

Market capitalization (06-Jun-2017)

717.7 m

Closing share price (06-Jun-2017)

15.3

Cash (31-Dec-2016)

158.5 m

EV

890.3 m
Acorda Therapeutics's current market capitalization is $717.7 m.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

336.4 m401.5 m492.7 m519.6 m

Revenue growth, %

19%23%5%

Cost of goods sold

66 m80 m92.3 m107.5 m

Gross profit

270.4 m321.5 m400.4 m412.1 m

Gross profit Margin, %

80%80%81%79%

R&D expense

53.9 m73.5 m149.2 m203.4 m

General and administrative expense

185.5 m201.8 m205.6 m235.4 m

Operating expense total

306.1 m365.1 m458.7 m555.6 m

EBIT

30.4 m36.4 m34 m(36 m)

EBIT margin, %

9%9%7%(7%)

Interest expense

(2.2 m)(9.3 m)(15.5 m)(16.5 m)

Interest income

668 k674 k440 k339 k

Pre tax profit

28.9 m28 m19.4 m(42.3 m)

Income tax expense

(8.3 m)6.7 m

Net Income

16.4 m17.7 m11.1 m(35.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

48 m182.2 m153.2 m158.5 m

Accounts Receivable

1 m

Current Assets

367.3 m409.1 m451.3 m272.7 m

PP&E

16.5 m46.1 m40.2 m34.3 m

Goodwill

183 m183.6 m280.6 m

Total Assets

607.1 m1.1 b1.1 b1.3 b

Accounts Payable

15.9 m17.8 m14.2 m26.9 m

Total Debt

331.1 m

Current Liabilities

96.6 m114.4 m90.6 m147.9 m

Common Stock

46 k

Additional Paid-in Capital

678.7 m761 m812.8 m921.4 m

Retained Earnings

(238.1 m)(220.4 m)(209.4 m)(244 m)

Total Equity

440.4 m540.3 m603 m664.2 m

Debt to Equity Ratio

0.5 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.4 x2 x1.9 x2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

16.4 m17.7 m11.1 m(35.6 m)

Depreciation and Amortization

7 m8.5 m15 m21.6 m

Accounts Receivable

(4.5 m)(1.4 m)744 k(20 m)

Inventories

(10.2 m)(6.7 m)

Accounts Payable

59.9 k59.9 k37.6 m

Cash From Operating Activities

6.2 m134.1 m(29 m)35.3 m

Purchases of PP&E

(4 m)(5.1 m)(5.9 m)(6.2 m)

Cash From Investing Activities

(45.1 m)(293.8 m)(85.2 m)(73.8 m)

Cash From Financing Activities

12 m352.9 m17.8 m45.9 m

Interest Paid

2 m4.5 m7.2 m6.1 m

Income Taxes Paid

2.6 m4.4 m4.7 m4.3 m
Numbers are in $, USDY, 2016

EV/EBIT

-24.7 x

EV/CFO

25.2 x

Revenue/Employee

971.2 k

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2 x

Acorda Therapeutics Market Value History

Acorda Therapeutics Job Categories

Acorda Therapeutics Online and Social Media Presence

Acorda Therapeutics Company Life and Culture

You may also be interested in